在非便秘的刺激性肠综合征患者中神经神经刺激的有效性:系统性审查
Ana Maria Garcia-Cabrera1, Fernando De la Portilla2, Rosa María Jiménez-Rodríguez3
1Virgen del Rocío University Hospital, Seville, Spain. anam.gcabrera@gmail.com.
Journal of gastrointestinal and liver diseases : JGLD
|September 29, 2023
概括
圣经神经刺激显示出改善非便秘性易怒肠综合征 (IBS) 患者的症状和生活质量的前景. 需要对更大规模的研究进行进一步的研究来证实这些发现.
科学领域:
- 胃肠病学 胃肠病学
- 神经胃肠病学 神经胃肠病学
背景情况:
- 刺激性肠综合征 (IBS) 是一种常见的功能性胃肠疾病,具有复杂的病理生理学,涉及肠-大脑轴的失调.
- 目前的IBS治疗是针对症状的,需要多学科的方法.
- 评估IBS的新型治疗策略至关重要.
研究的目的:
- 评估圣神经刺激 (SNS) 的有效性和安全性,特别是在非便秘的IBS患者中.
主要方法:
- 在主要数据库 (MEDLINE,CENTRAL,Web of Science) 进行了全面的文献搜索.
- 包括的研究使用标准化指南进行了质量评估.
- 选择了七篇相关文章,包括随机试验和试点研究.
主要成果:
- 在七项研究中,有五项报告说,在没有便秘的IBS患者中,圣神经刺激的结果是积极的.
- 症状严重程度和生活质量均有所改善.
- 在任何包括的研究中都没有报告任何严重的不良事件.
结论:
- 圣神经刺激证明了对管理非便秘性IBS的潜在有效性和安全性.
- 在审查的研究中没有报告任何严重不良事件.
- 建议进行更大的样本大小研究和更长的随访,以验证这些有希望的结果.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
197
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
197
Drugs for Treatment of Diarrhea-Predominant IBS
200
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
200
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
289
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
289
Irritable Bowel Syndrome I: Introduction
304
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
304
Irritable Bowel Syndrome III: Medical and Nursing Management
225
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
225
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
181
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
181


